Return to Article Details
DEVELOPMENT AND OPTIMIZATION OF SOLID LIPID NANOPARTICLES OF ERLOTINIB USING DESIGN OF EXPERIMENTS: IN VITRO DRUGRELEASE AND IN VIVO PHARMACOKINETIC STUDIES